Section - Quick Takes

01. Adverse Drug Reactions Associated With Drugs Prescribed in Psychiatry: A Retrospective Descriptive Analysis in a Tertiary Care Hospital

Published on April 1, 2022 Expired on April 1, 2024

James Phelps, M.D.

Research Editor - Psychopharmacology Institute

Key Points

Adverse drug reactions to psychiatric medications, when studied in hospital-based practice, are as one would expect: Metabolic effects from second-generation antipsychotics and extrapyramidal effects from first-generation antipsychotics.
Antidepressant-induced suicidal ideation is rare but not zero in reported data and is likely underreported.

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Text version

This is a Quick Take about adverse drug reactions. We’ll start with a little quiz. Question 1, what is the most common adverse drug reaction (ADR)? Question 2, which class of psychiatric medications causes ADRs most frequently? If you’re like me, you immediately start trying to answer the question. Weight gain is the most common ADR, thought I, and antipsychotics the most common class. But, of course, the right answer is, it depends.

Hi! Jim Phelps here for the Psychopharmacology Institute. The answer depends on whether you’re looking at inpatient records, outpatient records, or both and on whether you’re recording absolute or relative numbers—the sheer total of adverse reactions reports for a given medication or the number of those reports relative to the frequency with which that medication is prescribed. Of course, you could add more qualifications—the number of ADRs actually experienced vs those reported to a prescriber or those

Unlock this Quick Take and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Next Section

02. Repetitive Transcranial Magnetic Stimulation for Smoking Cessation: A Pivotal Multicenter Double‐Blind Randomized Controlled Trial

Learning Objectives:

After completing this activity, the learner will be able to:

Examine adverse drug reactions to psychiatric medications in small and large databases from around the world.
Assess the efficacy of transcranial magnetic stimulation for smoking cessation in a large randomized trial.
Compare the outcomes of multiple studies of initial treatments for major depressive disorder in a network meta-analysis of pharmacotherapy, psychotherapy, and their combination in acute and maintenance treatment.
Evaluate the relative effectiveness of ketamine and placebo when combined with either mindfulness psychotherapy or psychoeducation for the treatment of alcohol use disorder.
Consider the channels through which antidepressants cause manic switches in susceptible individuals.

Original Release Date: April 1, 2022

Review Date: March 1, 2024

Expiration Date: April 1, 2024

Relevant Financial Disclosures:

None of the faculty, planners, and reviewers for this educational activity have relevant financial relationships to disclose during the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.